NP Screen™

The Problem: Until NP Screen™, there were no early detection methods available

More than 80% of Nasopharyngeal Cancer (NPC) diagnosed cases from around the world are presented in the late stage of the disease, often requiring treatments that may include serious side effects from treatment.

NPC in its early stages is highly curable with a lower re-occurrence rate, and better prospects for long-term survival with just radiation therapy. Therefore, early diagnosis of the disease is critical for patient survival.

Even with recent advancements in medical treatment, survival rates and quality of life have not significantly improved for NPC patients. The main reason is due to the late stage detection with no alerting recognizable symptoms.

early detect

LightBulb

Our Solution: Paradigm Shift from Effective Treatment to Early Detection

Early detection improves survival rates from 30-40% to over 90%. NP Screen™ provides the only reliable and simple method for a regular screening program to help manage NPC for high and moderate risk patients.

Combined with the latest genetic technology, and advancement in research. Using an innovative, trans-oral brush process for direct sampling.
NP Screen™ bridges the gap between accuracy and non-invasiveness conventional methods such as endoscopy, biopsy and serology, etc. cannot provide.

Early genetic screening test for NPC

NP Screen™ is a simple, highly sensitive and specific genetic based screening test kit for the detection of Nasopharyngeal Cancer. Since it has been demonstrated that NPC tumor cells have copies of Epstein-Barr Virus DNA, NP Screen™ is designed to specifically measure the presence of EBV DNA as an indicator of the presence of NPC.

NP Screen™ has been specifically proven to provide s proven 99% level of sensitivity and specificity in the detection of NPC. The result is highly accurate and predictive of the presence of NPC, even in patients with clinically inconspicuous disease. Patients harboring the cancer without findings on endoscopy have also been found to be positive using this method.

NP Screen™ is now available to you for annual screening of early NPC detection.

product

Accurate, Simple, Non-invasive

The procedure is painless and takes no more than 1 minute to perform. NP Screen™ has been scientifically proven to provide a 99% level of sensitivity and specificity in detection of nasopharyngeal cancer.

The most accurate way to test for the presence of NPC is the NP Screen™ genetic test. This test accurately detects the presence of the Epstein-Barr virus in the genetic materials of the patient.

NP Screen™
Positive Predictive Value (PPV) Negative Predictive Value (NPV)
96.9% 99.7%

NP Screen™ has an incredibly high accuracy rate of 99%, an accuracy rate that compares favorably to other screening tests, including Mammograms (85-90%) and Pap Smears (71-81%).

The test directly samples cells from the nasopharyngeal area. In addition to its high level of accuracy, the test is very easy for patients to tolerate, since it only requires a simple brushing at the back of the throat.

The test is recommended to be repeated annually or semi-annually especially for individuals from high or moderate-risk endemic areas of the world, or for those with a family history of NPC. (Patients with a family history of NPC have 20 times the risk than even high risk populations.)

Back to Top